TL Ventures led the financing which included a new investor, Battelle Ventures, along with the existing investors Battelle, Safeguard Scientific, PA Early Stage Partners, Fletcher Spaght Ventures, L.P., Reservoir Venture Partners and James Richardson & Sons, Limited.
"This investment will allow us to quickly advance our technology toward commercialization," said Leslie Williams, President and CEO of Ventaira. "With this additional funding, we will complete development of our commercial inhalation device, advance the clinical program for our lead asthma compound and expand the formulation capabilities of our EHD technology platform. We are excited that our current investors have made this additional investment in the Company and to have Battelle Ventures as a new investor."
Devang Kantesaria, MD, at TL Ventures and lead investor commented, "Ventaira represents the rare opportunity to invest in a Company that will change the drug delivery landscape for respiratory medicines. The next 12 months represents an exciting time for the Company where the commercial potential and superiority of the EHD technology will be fully validated."
Page: 1 2 3 4 5
